[1]覃彩芳 来玉芹 蒋 娟 樊伯珍 牛 聪 郭钦源.卵巢癌患者血清CA125、D-二聚体、ApoE水平的变化及意义[J].大众科技,2023,25(6):71-75.
　Changes and Significance of Serum CA125, D-Dimer, and ApoE Levels in Ovarian Cancer Patients[J].Popular Science & Technology,2023,25(6):71-75.
点击复制

卵巢癌患者血清CA125、D-二聚体、ApoE水平的变化及意义()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
25
期数:
2023年6
页码:
71-75
栏目:
医药与卫生
出版日期:
2023-06-20

文章信息/Info

Title:
Changes and Significance of Serum CA125, D-Dimer, and ApoE Levels in Ovarian Cancer Patients
作者:
覃彩芳1 来玉芹1 蒋 娟1 樊伯珍2 牛 聪1 郭钦源1
（1.广西柳州市妇幼保健院，广西 柳州 530002；2.上海中医药大学附属普陀医院，上海 200062）
关键词:
卵巢癌; CA125; D-二聚体; ApoE; ROC曲线
Keywords:
ovarian cancer;  CA125;  D-dimer;  ApoE;  ROC curve
文献标志码:
A
摘要:
的：分析血清CA125、D-二聚体、ApoE在卵巢癌患者中的表达水平，并探讨其诊断价值，以期提高早期卵巢癌的确诊率。方法：通过回顾性分析2018年3月至2021年3月在上海中医药大学附属普陀医院妇科就诊的121例卵巢肿瘤患者的临床资料，其中术后病理组织学检查确诊为卵巢癌53例和卵巢良性肿瘤68例，分析其及同期本院体检中心50例健康志愿者血清中CA125、D-二聚体、ApoE的水平，制作ROC曲线，分别探讨CA125、D-二聚体、ApoE和三者联合在卵巢癌诊断中的价值。结果：卵巢癌组患者血清中CA125、D-二聚体、ApoE水平分别为380.61±401.94 U/L、2.22±2.56 mg/L、51.98±15.33 mg/L，均高于卵巢良性肿瘤组和正常对照组，差异有统计学意义（P＜0.05）；卵巢良性肿瘤组CA125、D-二聚体、ApoE水平分别为50.85±70.99 U/L，0.60±0.50 mg/L，43.82±26.93 mg/L，均高于正常对照组（均P＜0.05）；卵巢癌患者血清CA125、D-二聚体、ApoE水平随FIGO分期的增加而升高，差异均有统计学意义（均P＜0.05）；浆液性卵巢癌患者血清CA125、D-二聚体、ApoE水平高于非浆液性卵巢癌者，差异均有统计学意义（均P＜0.05）；ROC曲线显示CA125的曲线下面积（AUC）为0.805，D-二聚体的AUC为0.812，ApoE的AUC为0.709，三者联合诊断的AUC为0.835。结论：卵巢癌患者血清CA125、D-二聚体、ApoE均呈高表达，均较正常对照组升高，且随着FIGO分期增加而逐渐升高，对卵巢癌有辅助确诊意义，联合检测对卵巢癌的诊断价值高于各单项指标的检测，对卵巢癌的早期诊断、病情发展监测、预后评价具有更重要的意义。
Abstract:
Objective: To analyze the expression levels of serum CA125, D-dimer, and ApoE in ovarian cancer patients and explore their diagnostic value, in order to improve the diagnostic rate of early ovarian cancer. Methods: A retrospective analysis was conducted on the clinical data of 121 patients with ovarian tumors who visited the gynecology department of Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from March 2018 to March 2021. Among them, 53 patients were diagnosed with ovarian cancer and 68 patients with ovarian benign tumors through postoperative histopathological examination. The levels of CA125, D-dimer, and ApoE in the serum of 50 healthy volunteers from the same period’s physical examination center were analyzed and ROC curve was made to investigate the value of CA125, D-dimer, ApoE and the combination of CA125, D-dimer and Apoe in the diagnosis of ovarian cancer. Results: The serum levels of CA125, D-dimer and ApoE in ovarian cancer group were 380.61±401.94U/L, 2.22±2.56mg/L and 51.98±15.33mg/L, respectively, which were higher than those in benign ovarian tumor group and normal control group, and the difference was statistically significant (P<0.05). The levels of CA125, D-dimer and ApoE in benign ovarian tumor group were 50.85±70.99U/L, 0.60±0.50mg/L and 43.82±26.93mg/L, respectively, which were higher than those in normal control group (all P<0.05). The serum levels of CA125, D-dimer and ApoE in ovarian cancer patients increased with the increase of FIGO stage, and the differences were statistically significant (all P<0.05). Serum levels of CA125, D-dimer and ApoE in serous ovarian cancer patients were higher than those in non-serous ovarian cancer patients, and the differences were statistically significant (all P<0.05). ROC curve showed that the area under curve (AUC) of CA125 was 0.805, the AUC of D-dimer was 0.812, the AUC of ApoE was 0.709, and the AUC of combined diagnosis of the three was 0.835. Conclusions: The serum CA125, D-dimer, and ApoE levels in ovarian cancer patients are highly expressed, which are higher than those in the normal control group. They gradually increase with the increase of FIGO staging, and have auxiliary diagnostic significance for ovarian cancer. Combined testing has higher diagnostic value for ovarian cancer than the detection of various individual indicators, and has more important significance for early diagnosis, disease development monitoring, and prognosis evaluation of ovarian cancer.

参考文献/References:

1]　陈艳梅，张春蕾，龚振英，等. 卵巢癌患者四项血清肿瘤标志物水平的变化及意义[J]. 中国医药，2021，16(2): 267-270.[2] 刘楠. PLR、D-二聚体及CA125在卵巢癌中的诊断价值[D]. 延边: 延边大学，2020.[3] 李达，何静. 妇科恶性肿瘤患者凝血功能及D-二聚体水平变化及意义[J]. 中华实用诊断与治疗杂志，2016，30(6): 596-597.[4] 李文建. 载脂蛋白E影响巨噬细胞因子表达及分型的机制研究[D]. 石家庄: 河北医科大学，2015.[5] CHEN Y C, POHL G, WANG T L, et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer[J]. Cancer Research, 2005, 65(1): 331-337.[6] WAN Q, LIU Y, LV B, et al. Correlation of molecular tumor markers CA125, HE4, and CEA with the development and progression of epithelial ovarian cancer[J]. Iranian Journal of Public Health, 2021, 50(6): 1197-1205.[7] 谢幸，孔北华，段涛. 妇产科学: 第9版[M]. 北京: 人民卫生出版社，2018.[8] BAST R C, BADGWELL D, LU Z et al. New tumor markers: CA125 and beyond[J]. International Journal of Gynecological Cancer, 2005, 15(3): 274-281.[9] 刘燕，陈佳喜. 血清CA125、HE4及IL-6联合检测卵巢癌患者的意义分析[J]. 中国妇幼保健，2020，35(4): 639-641.[10] ZHANG F, ZHANG Z L. The diagnostic value of transvaginal sonograph (TVS), color dop-pler, and serum tumor marker CA125, CEA, and AFP in ovarian cancer[J]. Cell Biochemistry and Biophysics, 2015, 72(2): 353-357. [11] 肖叶，陈玉群，董严，等. 多种血清肿瘤标志物联合应用在卵巢癌诊断中的临床价值[J]. 国际检验医学杂志，2022，43(14): 1744-1748.[12] GIAMOUGIANNIS P, MARTIN-HIRSCH P L, MARTIN F L. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia[J]. Carcinogenesis, 2021, 42(3): 327-343.[13] 王海静，高萍，张晶晶，等. NLR、PLR联合CA125对上皮性卵巢癌诊断及预后评估的研究[J]. 中国妇产科临床杂志，2021，22(1): 30-32.[14] WU J, FU Z, LIU G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A Meta-analysis[J]. Medicine , 2017, 96(25): e7062. [15] 王翔，张雨洁. 恶性肿瘤患者凝血功能异常的研究进展[J]. 现代肿瘤医学，2016，24(8): 1325-1328.[16] SUEGA K, BAKTA I M. Correlation between clinical stage of solid tumor and D dimer as a marker of coagulation activation[J]. Acta Medica Indonesiana, 2011, 43: 162-167.[17] WU J, FU Z, LIU G, et al. Clinical significance of plasmaD-dimer in ovarian cancer Meta-analysis[J]. Medicine, 2017, 96(25): e7062.[18] 景志英，张颖. 血清D-二聚体、CA125、HE4在卵巢癌患者中的表达及诊断价值[J]. 中国卫生工程学，2021，20(2): 276-277.[19] TAVAZOIE M F, POLLACK I, TANQUECO R, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer[J]. Cell. 2018, 172(4): 825-840.[20] 卢朝晖. ApoE4基因与乳腺癌有关[J]. 英国医学杂志(中文版)，2000(1): 16.[21] 张宁，王颖娴，胡健，等. 血清CA199、C3、C4及脂类代谢水平在胰腺癌临床诊断中的应用[J]. 吉林大学学报(医学版)，2016，42(2): 295-300.[22] 王当锋. 抑癌蛋白UBIAD1的细胞亚定位以及它与H-Ras、ApoE的相互作用的研究[D]. 武汉: 华中科技大学，2013.[23] 陈汝琪. ApoE缺失通过激活细胞与基质粘附中的FAK-ERK信号通路促进卵巢癌的恶性进展[D]. 武汉: 华中科技大学，2019.

备注/Memo

备注/Memo:
【收稿日期】2022-08-25【基金项目】柳州市科技攻关与新产品试剂项目（2020NBAA0806）。【作者简介】覃彩芳（1994－），女，广西柳州市妇幼保健院中医科住院医师，硕士，研究方向为中医妇科。【通信作者】来玉芹（1979－），女，广西柳州市妇幼保健院中医科主任医师，硕士，从事中医妇科临床工作。
更新日期/Last Update: 2023-08-08